Literature DB >> 7082826

The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.

C J Carter, J G Kelton, J Hirsh, A Cerskus, A V Santos, M Gent.   

Abstract

We have compared the hemorrhagic and antithrombotic effects of a low molecular weight (LMW) heparin fraction and standard heparin in rabbits. Similar LMW heparin fractions have antithrombotic effects when tested in animals, but their hemorrhagic effects relative to standard heparin have not been established. Standard porcine mucosal heparin (mol wt 15,000 daltons) was depolymerized by nitrous acid to a low molecular weight fraction (mol wt 4600 daltons). Using equal USP units, the standard and Dep LMW heparin were compared in vitro, ex vivo, and in vivo. In vitro, when diluted in rabbit plasma, the Dep LMW heparin at equivalent anti-Xa activity showed less prolongation of thrombin clotting times or activated partial thromboplastin times. Ex vivo, platelets from rabbits treated with the Dep LMW heparin showed less inhibition of collagen-induced aggregation. The relative hemorrhagic properties of the two heparins were compared in vivo in rabbits using a sensitive blood loss assay, and the antithrombotic properties were compared in a thrombin-induced venous stasis model. By using an optimal threshold heparin dose in each test system, it was possible to demonstrate that equal USP units of Dep LMW heparin caused less blood loss but showed greater antithrombotic activity than standard heparin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082826

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

Review 1.  New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice.

Authors:  R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

2.  Adjunctive Pharmacologic Treatment: Focus on the Development of Low Molecular Weight Heparins.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

3.  Ventriculostomy-related cerebral hemorrhages after endovascular aneurysm treatment.

Authors:  Ian B Ross; Gurmeet S Dhillon
Journal:  AJNR Am J Neuroradiol       Date:  2003-09       Impact factor: 3.825

Review 4.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 5.  New data on the pharmacology of heparin and low molecular weight heparins.

Authors:  M M Samama; L Bara; I Gouin-Thibault
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 6.  Formulary management of low molecular weight heparins.

Authors:  W E Wade; B C Martin; J A Kotzan; W J Spruill; M A Chisoholm; M Perri
Journal:  Pharmacoeconomics       Date:  2000-01       Impact factor: 4.981

Review 7.  Low molecular weight versus unfractionated heparin. A clinical and economic appraisal.

Authors:  D Heaton; M Pearce
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

Review 8.  The pathogenesis and prevention of thromboembolic complications in patients undergoing total hip replacement.

Authors:  D K Potyk; H J Tabbarah
Journal:  J Gen Intern Med       Date:  1993-04       Impact factor: 5.128

9.  Clinical efficacy of low molecular weight heparin in postoperative thrombosis prophylaxis.

Authors:  U Schmitz-Huebner; H Bünte; G Freise; B Reers; C Rüschemeyer; R Scherer; H Schulte; J van de Loo
Journal:  Klin Wochenschr       Date:  1984-04-16

10.  Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: a meta-analysis.

Authors:  A Leizorovicz; G Simonneau; H Decousus; J P Boissel
Journal:  BMJ       Date:  1994-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.